Evidence of an untamed HIV epidemic among MSM and TGW in Rio de Janeiro, Brazil: a 2018 to 2020 cross-sectional study using recent infection testing
- PMID: 34132470
- PMCID: PMC8207443
- DOI: 10.1002/jia2.25743
Evidence of an untamed HIV epidemic among MSM and TGW in Rio de Janeiro, Brazil: a 2018 to 2020 cross-sectional study using recent infection testing
Abstract
Introduction: Monitoring the HIV epidemic and identifying populations among whom HIV is spreading is critical. We aimed to provide an estimate of the annualized HIV incidence rate using recency testing among cisgender men who have sex with men (MSM) and transgender women (TGW) at a reference centre in Rio de Janeiro, Brazil.
Methods: We evaluated MSM and TGW who sought HIV testing at the Evandro Chagas National Institute of Infectious Diseases-FIOCRUZ between March 2018 and January 2020. The Limiting Avidity assay (LAg) as part of a recent infection testing algorithm (RITA) was employed to identify recent infections (those with a normalized optical density ≤1.5 in the LAg that met all RITA criteria) among those who tested positive for HIV and the annualized HIV incidence was estimated.
Results and discussion: Out of 3053 individuals assessed, 2591 (84.9%) were HIV negative and 462 (15.1%) were living with HIV. Among these, 302 (65.4%) with stored samples available were evaluated and 73/302 (24.2%) were classified as recent infections. The annualized incidence rate estimate using a false recency rate of zero was 7.35% (95% CI 5.76% to 9.25%).
Conclusions: Our results suggest that the HIV epidemic in Rio de Janeiro, Brazil, continues to disproportionately burden vulnerable populations, including MSM and TGW despite the existence and availability of effective preventive and therapeutic interventions.
Keywords: HIV; MSM; diagnosis; incidence; recency; trans women.
© 2021 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.
Figures
References
-
- BRAZIL . Boletim Epidemiológico HIV/AIDS 2020 [Internet]. 2020. [cited 2021 Mar 14]. Available from: http://www.aids.gov.br/pt‐br/pub/2020/boletim‐epidemiologico‐hivaids‐2020
-
- Coelho LE, Torres TS, Veloso VG, Landovitz RJ, Grinsztejn B. Pre‐exposure prophylaxis 2.0: new drugs and technologies in the pipeline. Lancet HIV. 2019;6(11):e788–e799. - PubMed
-
- Mayer KH, Molina J‐M, Thompson MA, Anderson PL, Mounzer KC, De Wet JJ, et al. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre‐exposure prophylaxis (DISCOVER): primary results from a randomised, double‐blind, multicentre, active‐controlled, phase 3, non‐inferiority trial. Lancet. 2020;396(10246):239–54. - PMC - PubMed
-
- Landovitz R, et al. HPTN 083 Interim results: Pre‐exposure prophylaxis (PrEP)376 containing long‐acting injectable cabotegravir (CAB‐LA) is safe and highly effective for 377 cisgender men and transgender women who have sex with men (MSM, TGW). New Engl J Med. 2021. Accepted.
-
- Ministério da Saúde . Secretaria de Vigilância em Saúde. Manual técnico para o diagnóstico da infecção pelo HIV [Internet]. 2013. Available from: http://bvsms.saude.gov.br/bvs/publicacoes/manual_tecnico_diagnostico_inf...
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
